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Abstract
MicroRNAs (miRNAs) are small, noncoding RNAs transcribed from DNA that are 18–
24 nucleotides in length. A single miRNA has the capacity to regulate a large number of
target messenger RNAs (mRNAs), and the main function of miRNAs is to downregu‐
late gene expression. A large set of miRNAs is overexpressed or downregulated in various
human cancers compared with normal tissues, and gene silencing by miRNAs enhan‐
ces tumor malignancies.
In glioblastomas (GBMs), a number of miRNAs are reported to display aberrant expression
patterns,  and  miRNAs  have  been  shown  to  strongly  influence  cell  viability,  cell
proliferation, invasiveness, angiogenesis,  metabolism, and microenvironment. Since
early findings, the number of studies published on this subject has steadily increased,
elucidating numerous interesting miRNA-mediated mechanisms in the tumorigenesis of
GBM.
A number of studies have recently suggested that circulating miRNAs could be potential
biomarkers for cancer diagnosis. Not only the role of miRNAs in glioma development
but also their specificity makes them important candidate biomarkers that could provide
important characteristic information about a tumor and improve treatment and
prognosis. This review summarizes current progress and future directions in this
exciting and steadily expanding field.
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1. Introduction
Glioblastomas (GBMs) are the most common and intractable primary neoplasms of the central
nervous system (CNS). Gross total surgical excision followed by radiotherapy up to a total
dose of 60 Gy was the only accepted GBM management for decades because no chemothera‐
peutic agents significantly improved the survival of patients with GBM until the introduction
of temozolomide, an oral alkylating agent (1). Despite aggressive treatments, recurrence is
inevitable and fatal in GBMs. In a recent clinical study, the median survival was up to
approximately 20 months and the two-year survival rate was approximately 30~40% (2, 3).
Therefore, more efforts need to be made to change the poor prognosis of patients with GBM.
MicroRNAs (miRNAs) are small (18–24 nt), noncoding RNAs that are transcribed from the
intergenic or intronic regions of DNA. miRNAs regulate the expression levels or translational
levels of messenger RNAs (mRNAs) post-transcriptionally and affect to various biological
processes, such as cell proliferation, cell survival, differentiation, and metabolism (4). Primary
miRNAs (pri-miRNAs), transcribed from DNA and have short stem-loop structures (SLSs),
are processed into premature miRNAs (pre-miRNAs) and then finally processed into mature
miRNAs (5). A single miRNA has many targets of mRNAs, binding its target sites mostly in
the 3′ untranslated region (3′-UTR) of the mRNA. The main function of miRNAs is to down‐
regulate gene expression, and miRNAs can function either as tumor suppressors or as
oncogenes (6).
A number of miRNAs are reported to display aberrant expression patterns in GBMs (7). In
2005, the first miRNA dysregulation was identified in GBMs (8). miR-21 detected by northern
blot was overexpressed in GBM tissues when compared with non-neoplastic control tissues.
On the other hand, a systemic screen for miRNA aberrations by miRNA microarray in GBM
was performed by other researchers (7). Using miRNA microarray analysis, we previously
reported that miR-10b, miR-21, miR-183, miR-92b, and miR-106b are highly expressed in GBMs
compared with normal brain tissue (9). Several other reports have also identified these
miRNAs as being upregulated in GBMs (8). Recently, we reported that the expression of
miR-183 involved in HIF-1α expression and its downstream molecules (10). Since then, it has
been documented that miRNA dysregulation could play an important role in development
and progression.
2. MicroRNA expression in glioblastoma
Similar to other malignant tumors, GBM has the hallmarks of cancer: biological capabilities of
sustaining proliferative signaling, inducing angiogenesis, evading growth suppressors,
resistance to apoptosis, activating invasion and metastasis, genomic instability, reprogram‐
ming energy metabolism, limitless replicative potential, and evading immune destruction. It
is generally accepted that hallmark features of GBM are not only a reflection of genetic
abnormalities and aberrant signal transition but also the dysregulation of miRNA-mediated
translational control. The miRNA-mRNA interactions transform the short “nonsense”
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sequences into endogenous oncogenes or tumor suppressors. miRNA expression patterns
could define a tumor type, implying that certain changes in miRNAs might drive the malignant
transformation to a particular tumor. Therefore, whether a miRNA acts as an oncomiR or
tumor suppressor-miRNA depends on the regulated genes and cellular context.
The first report on altered miRNA expression in GBMs was published in 2005 (8). In this report,
miR-21 was shown to be highly upregulated and to have antiapoptotic capabilities in GBM
cells. These findings suggest that overexpressed miR-21 may function as an oncogene in GBMs
by blocking expression of key apoptosis-enabling genes (8). In the same year, Ciafre et al.
analyzed the global expression levels of 245 microRNAs in both GBM cell lines and patient
biopsies (7). A systemic screen for miRNA aberrations by microarray identified a set of
dysregulated miRNAs in GBM tissues, including the upregulation of miR-10b, miR-21, and
miR-25 and downregulation of miR-128 and miR-181a/181b-/181c (7). Since then, miRNA
expression in GBMs has been evaluated in several profiling studies. We previously reported
that miR-10b, miR-21, miR-183, miR-92b, and miR-106b are highly expressed in GBMs
compared with normal brain tissue, and miR-134, miR-302c, miR-324, miR-379, and
miR-368-3p are downregulated in GBMs (9). In 2008, Silber et al. reported 13 miRNAs to be
downregulated and three miRNAs to be upregulated in anaplastic astrocytomas and GBMs
(11). Furthermore, they revealed that expression levels of miRNA-124 and miRNA-137 were
significantly decreased compared with non-neoplastic brain tissue, and both of them induce
differentiation of adult neural stem cells. Another study carried out by Godlewski et al. found
8 microRNAs to be upregulated and 11 downregulated when analyzing 245 microRNAs in the
setting of GBM (12). A microarray-based study by Rao et al. analyzing 756 microRNAs
identified another 55 upregulated and 29 downregulated microRNAs in primary and secon‐
dary GBMs and anaplastic astrocytoma compared with controls (13). This study not only
validated the role of several deregulated microRNAs but also provided data for the develop‐
ment of a 23 microRNA signature pattern for distinguishing between anaplastic astrocytoma
and GBM (13).
3. Hallmarks of glioblastoma and microRNAs
3.1. Growth signal activation and microRNAs
Cell proliferation in GBM could be triggered by somatic alterations within the receptor tyrosine
kinase (RTK)-signaling pathways. The most important pathways in GBM are the phosphati‐
dylinositide 3-kinase (PI3K)/AKT and RAS/mitogen-activated protein kinase (MAPK) path‐
ways (14). Abnormally augmented signals downstream from RTKs enable tumor cells to
sustain proliferation that is under tight control in normal cells. At least 90% of GBM cases
harbor genetic alterations in RTK pathways. Epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor alpha polypeptide (PDGFRA), MET proto-oncogene
(MET), and fibroblast growth factor receptor (FGFR) are among the most commonly dysre‐
gulated RTKs in GBM (15). EGFR and PDGFRA are well-established oncogenes in GBM (16),
and thus, identification of their miRNA regulators following the discovery of functional
implications of miRNAs in GBMs is warranted.
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miR-7 is a common regulator of the PI3K/ATK and MAPK pathways, both of which are
launched by EGFR through its two direct targets, the transcription factors PI3K and Raf-1,
respectively (17). Human EGFR mRNA 3′-untranslated region contains three miR-7 target sites
(18). Transient expression of miR-7 in GBM cells strongly inhibited in vivo GBM xenograft
growth (17). Decreased expression of miR-128 correlates with aggressive human glioma
subtypes, and miR-128 represses growth and mediates differentiation by targeting oncogenic
EGFR and PDGFRA (19). The authors demonstrated that miR-128 suppresses glioma formation
in a glioma mouse model, suggesting miR-128 as a glioma tumor suppressor that targets RTK
signaling to repress gliomagenesis. miR-218 targets multiple components of RTK-signaling
pathways, including the EGFR pathway, and miR-218 repression increases the abundance and
activity of multiple RTK effectors (20). The expression of miR-218 is significantly decreased in
the mesenchymal subtype of GBM, and the miR-218-RTK-HIF2α-signaling axis promotes GBM
cell survival and tumor angiogenesis (20). A large-scale, genomewide miRNA expression
analysis revealed miR-219 was downregulated in GBM, and exogenous overexpression of
miR-219 in glioma cells inhibited proliferation and soft agar colony formation (21). In addition,
overexpression of miR-219-5p reduced the activity of PI3 kinase and MAP kinase in glioma
cell lines by targeting to EGFR (21). Moreover, overexpression of miR-133 decreased GBM cell
growth and increased cell apoptosis, whereas depletion of miR-133 increased cell growth (22).
The protein translation inhibition of EGFR by miR-133 was confirmed by a dual luciferase
reporter assay (22). miR-340 overexpression suppressed several oncogenes, including EGFR
(23). miR-340 induces glioma cells toward terminal differentiation and regulates glioma cell
development by downregulating ROCK1 expression (23). miR-491 directly targets EGFR,
CDK6, and Bcl-xL (24). Importantly, miR-491 is commonly codeleted with its adjacent
CDKN2A on chromosome 9p21.3 in GBM. As a negative regulator of EGFR expression,
miR-491 is a tumor suppressor gene. On the other hand, miR-148a expression was elevated in
GBM specimens compared with normal human brain and astrocytes (25). miR-148a is a
prognostic onco-miRNA that targets MIG6 and BIM to regulate EGFR and apoptosis in GBM
(25). By inhibiting MIG6 expression, miR-148a reduced EGFR trafficking to Rab7-expressing
compartments, including late endosomes and lysosomes. This process coincided with reduced
degradation and elevated expression and activation of EGFR (25). Furthermore, the protein
expression of EGFR decreased in cells with forced overexpression of miR-34a (26). Yin et al.
reported that both deletion of miR-34a and amplification of EGFR were associated with
significantly decreased overall survival of patients with GBM (26).
PDGFRA is a direct target of miR-34a, a downregulated miRNA in the proneural subtype
compared with the mesenchymal subtype of GBM (27, 28). miR-34a specifically affects the
growth of proneural glioma cells in vitro and in vivo (28). miR-34a repression in proneural
gliomas is only modestly dependent on p53. Derepression of PDGFRA by the downregulation
of miR-34a in the proneural subtype that results in a more proliferative phenotype may be
responsible for the difference in response to clinical treatment for GBM. Gene mutation or
amplification in MET is a relatively rare event in GBM (29). However, miR-34a expression
inhibited c-Met reporter activities in glioma cells. In addition, miR-34a levels in human gliomas
were inversely correlated with c-Met levels. Transient transfection of miR-34a into gliomas
strongly inhibited cell proliferation, cell cycle progression, cell survival, and cell invasion (30).
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MET is highly expressed in the mesenchymal subtype of GBM (31). miR-182 sensitized glioma
cells to TMZ-induced apoptosis, promoted glioma initiating cell (GIC) differentiation, and
reduced tumor cell proliferation via knockdown of c-Met, Bcl2L12, and HIF2A (32).
miR-144-3p specifically bound to the MET 3′-untranslated region (3′ UTR) and inhibited its
expression. miR-144 strongly repressed GBM cell proliferation and invasion by suppressing
MET in vitro and in vivo (33).
RAS signaling, upstream of MAP kinase, is reported to be regulated by miRNAs. Although
only 1% of GBMs have a RAS mutation or amplification, 10% of GBMs contain neurofibromin
1 (NF1) inactivating genetic alterations that lead to hyperactive RAS activity by enhancing the
intrinsic GTPase activity (29). Two recent reports focused on miRNAs targeting RAS in GBMs
and showed that miR-143 directly targets N-RAS (34) and that let-7a directly targets K-RAS
(35). Low expression of let-7a was correlated with a poor prognosis of primary GBM patients
(35). In addition, miR-124 governs glioma growth and angiogenesis and enhances chemosen‐
sitivity by targeting R-RAS and N-RAS (36). In addition, miR-124 inhibits the MAP kinase
pathway by repressing SOS1 mRNA (37). Moreover, these miRNAs are all downregulated in
GBM specimens, underlying the malignant transformation.
Phosphatase and tensin homolog (PTEN) and NF1 are the most important negative regulators
of cell proliferative pathways. The inactivated genetic mutations of NF1 and PTEN are found
in 10 and 41% of GBM cases, respectively (29). NF1 is targeted by miR-9, which is an miRNA
upregulated in GBM and promotes the proliferation and migration of glioma cells (38, 39). In
addition, NF1 is a direct target of miR-514a, and over-expression of miR-514a inhibited NF1
expression, which correlated with increased survival cells (40). The protein phosphatase
activity of PTEN is involved in cell proliferation, preventing cells from growing. miR-26a,
frequently amplified at the DNA level in human gliomas, is identified as a direct regulator of
PTEN expression (41). miR-26a-mediated PTEN repression in a murine glioma model enhan‐
ces de novo glioma formation (41). Overexpression of miR-26a in PTEN-competent and PTEN-
deficient GBM cells promoted tumor growth in vivo and further increased growth in cells
overexpressing CDK4 or CENTG1 (42). Guo et al. reported that c-Myc modulates genes
associated with oncogenesis in GBM through deregulation of miRNAs via the c-Myc-miR-26a-
PTEN-signaling pathway (43). CREB, a proto-oncogenic transcription factor that is overex‐
pressed in gliomas, can promote gliomagenesis by modulating the expression of oncogenic
miR-23a, which represses PTEN directly (44). miR-23a-mediated suppression of PTEN led to
the activation of AKT/ERK pathways and epithelial-mesenchymal transition (EMT) (45).
miR-17-5p (46), and miRNA-1908 (47) directly target PTEN in GBMs. Overexpression of
miR-17 prolongs GBM cell survival and increases cell motility, and induces HIF-1α activation
in response to stress by targeting PTEN. (46). miR-1908 promotes proliferation, invasion, and
sphere formation in GBM cells by targeting PTEN, and PTEN levels are inversely correlated
with miR-1908 levels in GBM tissues (47). The expression of PTEN-targeting miR-17-5p,
miR-19a, miR-19b, miR-21, miR-130b, miR-221, and miR-222 was significantly higher in
irradiated glioma cells than in nonirradiated cells, and the PTEN expression levels were lower
in the irradiated glioma cells than in the nonirradiated cells (48).
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In recent years, molecular target therapy-targeting RTK pathways has been one of the most
exciting developments in cancer therapy, and certain molecular targeted drugs have been
clinically validated. However, for GBMs, no effective molecular targeted drug has yet been
developed. By understanding the roles of miRNAs in growth signal activation, miRNA-based
treatments should also be taken into consideration either alone or in combination.
3.2. Sustained angiogenesis and microRNAs
New growth in the vascular network is important because the proliferation, as well as
metastatic spread, of tumor cells depends on an adequate supply of oxygen and nutrients and
the removal of waste products. GBMs have a strong angiogenetic property because GBMs
possess glomeruloid microvascular proliferation, a hallmark of GBMs (49). GBMs stimulate
new blood vessel formation through processes driven primarily by vascular endothelial
growth factor A (VEGF-A), the most established proangiogenic protein in the VEGF family.
The overexpression of VEGF-A, and subsequent activation of its receptors, is an important
event during glioma progression (50).
miRNA-205, an miRNA significantly downregulated in GBMs, can specifically suppress
expression of VEGF-A directly (51). Moreover, miRNA-205 induces apoptosis and depresses
the invasion of glioma cells in vitro (51). VEGF-A upregulation can be induced by hypoxia
inducible factor 1 alpha subunit (HIF-1α), which is negatively regulated by the von Hippel-
Lindau (VHL) tumor suppressor (52). HIF-1α levels were upregulated in glioma cells following
transfection with miR-183 mimic RNA, and VEGF-A and glucose transporter 1 (GLUT1), which
are downstream molecules of HIF-1α, were upregulated in cells transfected with miR-183 (10).
miR-21, miR-23b, and miR-566 are reported to target VHL and decrease the production of the
VHL protein, upregulating VEGF-A expression. miR-21 directly targets VHL and peroxisome-
proliferator-activated receptor a (PPARa), and miR-21 regulates EGFR/AKT signaling through
VHL/β-catenin and the PPARa/AP-1 axis (53). miR-21 significantly colocalized with the
hypoxia- and angiogenesis-associated markers HIF-1α and VEGF (54). Downregulation of
miR-23b triggered growth inhibition, induced apoptosis, and suppressed invasion of glioma
in vitro (55). miR-23b deletion decreased HIF-1α/VEGF expression and suppressed β-catenin/
Tcf-4 transcription activity by targeting VHL (55). Inhibition of miR‑566 expression increases
the expression levels of VHL, decreases the expression levels of VEGF, and inhibits the invasive
and migratory abilities of GBM cells (56). Moreover, miR-7 downregulates the expression of
O-linked N-acetylglucosamine transferase (OGT) involved in the VEGF-signaling pathway,
leading to a profound reduction in vascularization, similar to the antiangiogenic drug sunitinib
(57).
miR-101 is downregulated in GBMs and targets EZH2, a histone methyltransferase affecting
gene expression profiles in an epigenetic manner. Inhibition of EZH2 by miR-101 attenuated
GBM cell growth, migration, and GBM-induced endothelial tubule formation (58). Ectopic
expression of miR-137 inhibited angiogenesis in a SCID mouse xenograft model. EZH2 was
identified as a direct target of miR-137, and EZH2 overexpression can rescue the inhibitory
effect of miR-137 on cell proliferation and angiogenesis (59). A key step in angiogenesis is the
upregulation of growth factor receptors on endothelial cells. miR-296 level is increased in
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primary tumor endothelial cells isolated from GBM tissues (60). Overexpressed miR-296
enhances angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine
kinase substrate (HGS), results in upregulation of the VEGF receptoe-2 and PDGF receptor-β
(60). miR-93 promotes angiogenesis by suppressing integrin-β8 (61). In vivo studies revealed
that miR-93-expressing cells induced blood vessel formation, allowing blood vessels to extend
to tumor tissues in high densities (61). Angiogenesis promoted by miR-93 in return facilitated
cell survival, resulting in enhanced tumor growth. miR-17∼92 promotes angiogenesis and
tumor growth by downregulation of clusterin (62). Specifically, miR-17-5p and miR-20 reduce
the expression of the type-II TGFβ receptor and miR-18 limits the expression of Smad4, namely
miR-17∼92 attenuates the TGFβ-signaling pathway to shut down clusterin expression, thereby
stimulating angiogenesis and tumor cell growth.
Because angiogenesis is a hallmark of GBM, targeting therapies against angiogenesis using the
VEGF antibody was previously considered to be promising in GBM. However, recently, two
phase-III studies revealed that the addition of the VEGF antibody bevacizumab to radiother‐
apy-temozolomide did not improve survival in patients with GBM, although improved
progression-free survival and maintenance of baseline quality of life and performance status
were observed with bevacizumab (2, 3). Therefore, new therapeutic targets or strategies need
to be developed. To make progress, a better understanding of the miRNAs contributing to
angiogenesis will lead to more effective antiangiogenic therapy for patients with GBM.
3.3. Insensitivity to antigrowth signals and microRNAs
To proliferate without limit, GBM cells must circumvent biologically programmed pathways
that negatively regulate cell proliferation. There are two major tumor suppressor genes,
retinoblastoma 1 (RB1) and tumor protein p53. Similarly, a better understanding of the
dysfunction of the RB1 and p53 pathways should also implicate the roles of dysregulated
miRNAs. The mutation of p53 results in the inability to stop further cell-cycle progression
triggered by oncogenic signals (63). miR-10b, one of the most studied miRNAs in GBMs, is
highly upregulated in human GBM and pleiotropically regulates invasion, angiogenicity, and
apoptosis of GBM cells. The pleiotropic effect of miR-10b is caused by its suppression of
multiple tumor-suppressive genes, including p53 (7, 64, 65). miR-10b directly targets p53 in
GBM, giving the tumors a way to evade growth control and enable persistent cell proliferation
by perturbing the miRNAs expression.
Moreover, p53 signaling is under the precise control of the negative regulator mouse double
minute 2 (MDM2). MDM2 regulates the ubiquitin-dependent degradation and transcriptional
activity of p53 (66). MDM2 mRNA is upregulated in both GBM cell lines and samples (67), and
the upregulation could be a consequence of the downregulation of miR-17, miR-181b, miR-25,
or miR-32, which directly target MDM2 gene expression (46, 67, 68). It is worth noting that
miR-25 and miR-32 are two miRNAs repressed by p53, suggesting a feedback circuit between
p53 and MDM2 mediated by miRNAs (67). The feedback circuit can explain the overexpression
of miR-25 in GBM reported by several separate studies, in which the miRNA is meant to be
downregulated to increase MDM2 expression and thus inactivate p53 (7, 39, 69). In addition,
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miR-181b is downregulated in GBM samples, further indicating that miRNA contributes to
the complexity of the pathological progression of gliomas (68).
Another key tumor suppressive is p16INK4a, an important inhibitor of RB pathway (70),
namely p16INK4a can bind specifically to CDK4/6 and inhibit the catalytic activity of CDK4/6-
cyclin D complexes (71). Approximately, 80% of GBMs have one or more alterations affecting
the RB1 function. In addition to targeting p53 in GBMs, miR-10b also targets p16INK4a, and
the inhibition of miR-10b leads to cell cycle arrest (65). miR-26a also targets RB1 in GBMs.
Additionally, CDK-cyclin complex-mediated phosphorylation is one of the main mechanisms
by which RB1 protein is inactivated (72). The frequent gain-of-function mutations on CDK4/6-
cyclin D complexes underscore their importance and potential in the development and
progression of GBM. miR-124 is reported to radiosensitize human glioma cells by downregu‐
lating CDK4 (73), whereas CDK6 is a direct target of miR-138 (74) and miR-491-3p/5p (24).
miR-195 inhibited glioma cell proliferation by downregulating expression of cyclin D1 and
cyclin E1, via directly targeting cyclin D1 and cyclin E1 mRNA (75). Notably, those miRNAs
that target cyclin-CDK complexes are all downregulated in GBM samples (69).
3.4. Invasion in the brain and microRNAs
The invasive propensity of glioma cells remains the major obstacle to improving the poor
outcomes of patients with GBM. GBM cells prefer to migrate through the tortuous extracellular
spaces of the brain. Therefore, it is supposed that the interaction of invading glioma cells with
the extracellular matrix (ECM) is crucial in the initiation of invasion and migration. Generally,
cell attachment is mediated by interactions between cell-cell and cell-ECM receptors, including
integrins and cadherins, and degradation of ECM components by metalloproteinases is
essential for cell detachment (76). The matrix metalloproteinases (MMPs) and a disintegrin
and metalloproteinases (ADAMs) are two distinct types of metalloproteinases secreted by
glioma cells to overcome the dense matrix, and the proteolytic activity can be blocked by
endogenous metalloproteinase inhibitors, such as tissue inhibitors of metalloproteinase
(TIMPs) and reversion-inducing-cysteine-rich protein with kazal motifs (RECK) (76).
miR-218 expression has been found to be significantly downregulated in GBM tissue samples
(77). Several studies have shown that miR-218 is a negative regulator of invasion in GBM
through various pathways (77, 78). miR-218 has been reported to target the mRNA of Lef1, the
transcription factor that is upregulated by β-catenin (77). Suppression of Lef1 leads to the
reduction of MMP-2, MMP-7, and MMP-9 activity and inhibition of invasion in vitro (79).
Another mechanism through which miR-218 negatively regulates GBM invasion is targeting
IKKβ mRNA along with reducing the transcription of NF-kB. NF-kB is a transcription factor
that is important in many cellular processes and has been strongly linked to the migration and
invasion of various cancer cells (78). NF-kB's target genes include MMP-9; therefore, its
inhibition by miR-218 causes a decrease in invasion.
MMP-9 is a direct target of miR-491-5p, which is upregulated in GBM (24). miR-491-5p
expression has been reported to reduce cell proliferation and invasion by targeting MMP9 (80).
miR-491-3p also reduces the invasiveness of GBM cells by targeting the mRNA of insulin-like
growth factor-binding protein 2 (IGFBP2). MMP-9 is also a direct target of miR-211 (81). MMP-3
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is targeted by miR-152 (82). Additionally, ADAM17, a non-MMP, is under the direct regulation
of miR-145 (83). It is clear that if glioma cells lose the control of MMPs and ADAMs by miRNAs,
ECM homeostasis is compromised and the combined activity of these proteases remodels the
ECM to favor tumor invasion. miR-101 is a tumor suppressor that is downregulated in GBM,
as well as other cancers. (58). It has been shown to downregulate the invasion of glioma cells,
as well as proliferation and migration, by targeting the transcription factor Kruppel-like factor
6 (KLF6). This suppression of KLF6 reduced the expression of chitinase-3-like protein 1
(CHI3L1) and inactivated MEK1/2 and PI3K signaling (72). miR-101 downregulation has been
shown to result in EZH2-induced proliferation, migration, and angiogenesis in GBM (74).
Similarly, miR-152 is a tumor suppressor that is often downregulated in cancers, including in
GBM. It was shown to suppress the invasion of glioma stem cells, as well as cell proliferation,
migration, invasion, and apoptosis. It has been reported that miR-152 exerts its tumor-
suppressing effects by targeting the transcription factor Kruppel-like factor 4 (KLF4). This
suppression of KLF4 causes the transcriptional downregulation of galectin-3 (LGALS3) and
the inactivation of MEK1/2 and PI3K signaling (75).
Because the MMPs and ADAMs each comprises more than 20 members, targeting a single
target appears to be nonessential in cancerous diseases, which provides miR-21 with an
opportunity to broadly inhibit metalloproteinase function. miR-21 regulates multiple genes
associated with glioma cell migration and invasion, including the RECK and TIMP3 genes,
which are inhibitors of matrix metalloproteinases (84).
In addition, interactions with the ECM are mostly mediated by integrins, which enable cells
to sense the extracellular environment and adjust their behavior to environmental cues.
miR-124, frequently downregulated in GBM, targets β1 integrin and is shown to affect glioma
cell migration and invasion in vitro (85). PPP1R13L (protein phosphatase 1, regulatory subunit
13 like), an inhibitory member of the apoptosis-stimulating protein of p53 family (IASPP), was
found to be a direct target of miR-124 in GBM cells. miR-124-mediated PPP1R13L regulates
invasion of GBM cells (86). Cai et al. found that miR-542-3p expression was decreased in GBM
cells, and miR-542-3p suppressed GBM cell invasion by not only targeting AKT1 but also
directly downregulating its two important upstream regulators, ILK (integrin-linked kinase)
and PIK3R1 (87). miR-181 family is downregulated in GBM and is inversely correlated with
activities of NF-kB-targeting genes. Furthermore, miR-181b was shown to suppress epithelial-
mesenchymal transition (EMT) by targeting KPNA4 (88). miR-181c overexpression inhibits
TGF-β signaling by downregulating TGFBR1 (transforming growth factor, beta receptor 1),
TGFBR2 and TGFBRAP1 (transforming growth factor, beta receptor-associated protein 1)
expression. miR-181c expression levels are correlated with poor prognosis of patients with
GBM.
miR-125a are downregulated in GBMs and directly target the 3′-UTR of podoplanin (PDPN)
and inhibit invasion, apoptosis, and proliferation of GBMs. In addition, miR-125a inhibits
Nrg1, one of the most active members of the EGF-like family, and suppresses the proliferation
and migration of GBM cells in vitro and in vivo (89). miR-203 expression is decreased in
anaplastic astrocytoma and GBM tissues. Forced expression of miR-203 was shown to suppress
glioma cell proliferation, migration, and invasion, by disrupting the Robo1/ERK/MMP-9-
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signaling axis (90). In addition, miR-203 inhibits the proliferation and invasion by directly
targeting phospholipase D2 (PLD2) (91). miR-29b expression, downregulated in GBMs, was
inversely proportional to that of BCL2-like 2 (BCL2L2) mRNA or protein (92). Interestingly,
BCL2L2 mRNA is highly expressed in the mesenchymal type of GBM. BCL2L2 repression is
of central importance to miR-29b antitumor activity in migration, invasion, and angiogenesis.
Moreover, miR-29b regulates PDPN, which promotes glioma invasion.
miR-10b is overexpressed in GBM and induces glioma cell invasion by modulating expression
of RhoC, MMP-14, and uPAR (urokinase-type plasminogen activator receptor) via HOXD10
(93). Multifocal lesions of malignant gliomas were associated with higher expression levels of
miR-10b (9). Dong et al. reported that not only miR-10b inhibition but also miR-21 inhibition
could exert synergistic inhibition of the invasion of glioma cells. miR-10b pleiotropically
regulates invasion, angiogenicity, and apoptosis of glioma cells by the suppression of multiple
tumor suppressors, including p53, FOXO3, HOXD10, and NOTCH1 (64). miR-155 has been
identified to be an oncomiR and is highly expressed in several solid cancers, including GBM.
Knockdown of miR-155 sensitizes glioma cells to the chemotherapy of temozolomide by
targeting p38 isoforms of mitogen-activated protein kinase 13 (MAPK13) and MAPK14 (94).
In sum, the roles of miRNAs in glioma cell invasion or migration further our understanding
of the genesis of the aggressive glioma phenotype. Some of these miRNAs have been discov‐
ered, whereas more still remain to be found. The blockade of excessive pro-invasive miRNAs
or the restoration of weakened anti-invasive miRNAs will provide extra treatment options for
advanced-stage gliomas that are marked by poor prognoses for decades (Table 1).
Hallmarks of
glioblastoma
miRNAs Targets Expression Function Ref
Growth signal
activation
miR-7 EGFR, PI3K,
Raf-1
down downregulate PI3K/ATK
and MAPK
pathways
Liu (17),
Webster (18)
miR-128 EGFR, PDGFRAdown downregulate PI3K/ATK
and MAPK
pathways
Papagiannakopoulos
(19)
miR-218 EGFR down downregulate PI3K/ATK
and MAPK
pathways
Mathew (20)
miR-219 EGFR down downregulate PI3K/ATK
and MAPK
pathways
Rao (21)
miR-133 EGFR down downregulate PI3K/ATK
and MAPK
pathways
Xu (22)
miR-340 EGFR down induce terminal differentiation Huang (23)
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Hallmarks of
glioblastoma
miRNAs Targets Expression Function Ref
miR-491 EGFR, CDK6,
Bcl-xL
down inhibit cell proliferation,
negative regulator of EGFR
Li (24)
miR-148a MIG6, BIM up reduce EGFR trafficking Kim (25)
miR-34a PDGFRA down inhibit cell proliferation and
cell cycle progression
inhibit cell survival invasion
Genovese (27), Silber (28)
miR-182 MET, Bcl2L12,
HIF2A
promote glioma initiating
cell differentiation
Kouri (32)
miR-144-3p MET down repress GBM cell
proliferation and invasion
Lan (33)
let-7a K-RAS down downregulate PI3K/ATK
and MAPK pathways
Wang (35)
miR-143 N-RAS down inhibit cell proliferation Wang (34)
miR-124 SOS1, R-RAS down inhibit cell proliferation Shi (36), Lv (37)
miR-9 NF1 up inhibit cell proliferation Tan (38)
miR-26a PTEN up promote tumor growth Huse (41)
miR-23a PTEN up activate of AKT/ERK
pathways and EMT
Tan (44), Tian (45)
miR-17-5p PTEN up formation of colonies and
neurospheres
Li (46)
miRNA-1908 PTEN up promote the tumor forming
potential and anchorage-
independent growth
Xia (47)
miR-19a PTEN up promote tumor growth Tokudome (48)
miR-19b PTEN up promote tumor growth Tokudome (48)
miR-21 PTEN up promote tumor growth Tokudome (48)
miR-130b PTEN up enhance stem cell-like
phenotype
Tokudome (48)
miR-221 PTEN up promote tumor growth Tokudome (48)
miR-222 PTEN up promote tumor growth Tokudome (48)
Sustained
angiogenesis
miR-205 VEGF-A down inhibit expression of VEGF-A
induce apoptosis and depress
the invasion
Yue (51)
miR-183 IDH2 up increase HIF1 expression Tanaka (10)
miR-21 VHL, PPARa up regulate EGFR/AKT
signaling
Harmansen (54)
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Hallmarks of
glioblastoma
miRNAs Targets Expression Function Ref
miR-23b VHL up inhibit tumor growth and
invasion, induce apoptosis
Chen (55)
miR-566 VHL up inhibit invasion and migration Xiao (56)
miR-7 OGT down reduce vascularization Babae (57)
miR-101 EZH2 down attenuate GBM growth and
migration/invasion
Smits (58)
miR-137 EZH2 down inhibit cell proliferation and
angiogenesis
Sun (59)
miR-93 Integrin-β8 up promote tumor growth and
angiogenesis
Fang (61)
Insensitivity to
antigrowth
signals
miR-10b p53, p16INK4a up promote cell cycle Gabriely (65)
miR-17-3p MDM2 inhibit tumor progression Li (46)
miR-181b MDM2 down inhibit tumor progression Suh (67)
miR-25-3p MDM2, p53 up inhibit cellular proliferation Suh (67)
miR-32-5p MDM2, p53 up inhibit cellular
proliferation
Suh (67)
miR-26a RB1 up promote cell proliferation Lundberg (72)
miR-124 CDK4 down cell cycle arrest Deng (73)
miR-138 CDK6 down cell cycle arrest Qiu (74)
miR-491-
3p/5p
CDK6 down cell cycle arrest Li (24)
miR-195 cyclin D1, cyclin
E1
down cell cycle arrest Hui (75)
Invasion and
metastasis
miR-218 IKKβ, Lef1 down inhibit cell invasion Liu (77), Song (78)
miR-491 IGFBP2, MMP9 down reduce cell proliferation and
invasion
Yan (80)
miR-211 MMP9 down reduce cell invasion Asuthkar (81)
miR-101 KLF6, EZH2 down reduce invasion of glioma
stem cells
Smits (58), Qiu (74)
miR-152 MMP3, KLF4 down reduce cell invasion and
angiogenesis
suppress invasion of glioma
stem cells
Zheng (82), Hui (75)
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Hallmarks of
glioblastoma
miRNAs Targets Expression Function Ref
miR-145 ADAM17 down reduce glioma cell invasion
and angiogenesis
Lu (83)
miR-21 TIMP3, RECK up promote cell invasion Gabriely (84), Zhao (86)
miR-124 β1 integrin,
IASPP
down suppress cell migration and
invasion
Fowler (85)
miR-542-3p AKT1 down suppress cell invasion Cai (87)
miR-181b KPNA4 down inhibit cell invasion and
proliferation
Wang (88)
miR-181c TGFBR1,
TGFBR2,
TGFBRAP1
down inhibit cell invasion and
proliferation
Wang (88)
miR-125a PDPN, Nrg1 down inhibit invasion and
proliferation
Yin (89)
miR-203 PLD2 down suppress cell proliferation
and invasion,disrupt the
Robo1/ERK/MMP-9
signaling axis
Dontula (90), Chen (91)
miR-29b BCL2L2, PDPN down inhibit glioma invasion Chung (92)
miR-10b HOXD10,
FOXO3,
NOTCH1
up induce glioma cell invasion Sun (93)
miR-155 MAPK13,
MAPK14
up regulates glioma cells
invasion and chemosensitivity
Liu (94)
Antiapoptosis miR-21 PDCD4,
HNRPK,
TP53BP2, p63
up antiapoptosis Corsten (95), Gaur (96)
miR-92a BCL2L11 up antiapoptosis Papagiannakopoulos (97)
miR-92b NLK up antiapoptosis Niu (98)
miR-93 ITGB8 up antiapoptosis Fang (61)
miR-221 p27, p57 up antiapoptosis Medina (100)
miR-222 p27, p57 up antiapoptosis Medina (100)
Genome
instability and
mutation
miR-106a up DNA replication and
mitosis
Liu (101)
miR-106b RBL1, RBL2 up DNA replication and
mitosis
Liu (101)
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Hallmarks of
glioblastoma
miRNAs Targets Expression Function Ref
miR-17-92 up DNA replication and
mitosis
Liu (101)
miR-20 DNA replication and
mitosis
Liu (101)
miR-221 p27 up Cell cycle chechpoint
regulation
Gillies (103)
miR-222 p27 up Cell cycle chechpoint
regulation
Gillies (103)
miR-155 MLH1, MSH2,
MSH6
up DNA mismatch repair Liu (94)
miR-125b p53, MXD1 down cell cycle arrest to repair
damaged DNA
spindle assembly checkpoint
Wan (104), Le (105)
miR-29 PIK3R1,
CDC42
down upregulate p53 Park (106)
miR-34 CCND1,
CCNE2,
CDK4, MET,
MYC, SNAI1,
and SIRT1
down DNA damage response
upregulate p53 downstream
molecules
He (107)
miR-101 ATM,
PRKDC
down DNA repair regulate non-
homologous end joining of
DNA double strand breaks
Yan (109)
Li (111)
Tumor-
promoting
inflammation
miR-21 LRRFIP1 up regulate NF-kB signaling
pathway
miR-146a TRAF6,
IRAK1
regulate NF kB
activation
Taganov (112), Park (113)
miR-124 down inhibit STAT3 pathway Wei (117)
Reprogramming
energy
metabolism
miR-451 CAB39 up regulate LKB1/AMPK
signaling activity
Godlewski (124)
mir-145 c-Myc, Sox9,
ADD3
down reduce Lin28/Lin28b
transcription
Rani (130), Gan (132)
miR-34c c-Myc regulate c-Myc mRNA
stability and translation
Masui (134)
Neurooncology - Newer Developments40
Hallmarks of
glioblastoma
miRNAs Targets Expression Function Ref
let-7 RAS, Myc,
CCND1, LIN28,
HMGA2
down regulate glucose
metabolism
Boyerinas (135)
let-7a K-ras down regulate glucose
metabolism
Boyerinas (135)
miR-326 PKM2, NOB1 down regulate glucose
metabolism RNA
metabolism
Kefas (136), Zhou (137)
Evading
immune
destruction
miRs-29b down differentiation of tumor-
associated macrophage
Graff (140)
miR-125a down differentiation of tumor-
associated macrophage
Graff (140)
miR-146a down differentiation of tumor-
associated macrophage
Graff (140)
miR-155 C/EBPβ up lead to and inversion of M2
into M1 macrophages
Graff (140)
miR-221 STAT1,2 up phosphorylation of STAT1
and STAT2
Zhang (143)
miR-222 STAT1,2 up phosphorylation of STAT1
and STAT2
Zhang (143)
miR-20a NKG2DL up immune evasion of glioma
cells at the level of the
NKG2D recognition
pathway
Codo (146)
miR-93 NKG2DL up immune evasion of glioma
cells at the level of the
NKG2D recognition
pathway
Codo (146)
miR-106b NKG2DL up immune evasion of glioma
cells at the level of the
NKG2D recognition
pathway
Codo (146)
miR-138 CTLA-4, PD1 down tumor regression Wei (147)
Table 1. Hallmarks of glioblastoma and microRNAs.
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3.5. Antiapoptosis and microRNAs
Among the tumor-associated miRNAs, miR-21 is frequently overexpressed in various types
of tumors, including GBMs (7, 9), and plays a critical role in cell death and apoptosis. Knock‐
down of miR-21 in cultured GBM cells triggered activation of caspases and led to increased
apoptotic cell death (8). miR-21 knockdown disrupts glioma growth in vivo and displays
synergistic cytotoxicity when combined with the agent tumor necrosis factor-related apoptosis
(s-TRAIL), leading to an increase in caspase activity (95). In particular, it was reported that the
downregulation of miR-21 in GBM-derived cell lines resulted in an increased expression of a
specific target, PDCD4 (programmed cell death 4), a known tumor suppressor gene, with a
consequent decrease in proliferation and increase in apoptosis (96). Furthermore, miR-21
regulated a network of p53, TGF-b, and mitochondrial apoptosis tumor suppressor genes in
GBM cells, targeting HNRPK (heterogeneous nuclear ribonucleoprotein K), TP53BP2 (tumor
protein p53-binding protein 2), and p63, a member of the p53 family of genes (97).
miR-92a and miR-92b, upregulated in glioma, target BCL2L11 (98) and NLK (99), respectively.
Their inhibition promotes tumor-suppressive phenotypes through the induction of apoptosis.
In addition, miR-93 was found to be upregulated in glioma specimens and resulted in an
enhancement in cell survival, promoting sphere formation, and augmenting tumor growth by
suppressing the expression of ITGB8 target (61).
miR-221 and 222 were extensively investigated in glioma. These miRNAs were found to be
upregulated in this cancer, and both were reported to target the cell growth-suppressive cyclin-
dependent kinase inhibitors p27 and p57 (100).
3.6. Genome instability and microRNAs
Genomic instability is defined as a high frequency of mutations within the genome, including
changes in nucleic acid sequences, chromosomal rearrangements, or aneuploidy. The stability
of the human genome is maintained by multiple mechanisms such as the cell cycle checkpoint,
DNA damage response, and mitotic separation machinery. Defects in the DNA damage
response could cause genomic DNA mutations, deletions, insertions, or gross chromosomal
gains and losses upon cell division and subsequently lead to cancer. Genomic instability is
present in GBM and affects the prognosis of patients.
Several members of the miR-106b-25 cluster and its paralog miR-17-92 cluster were associated
with DNA replication and mitosis. Overexpression of miR-106b-5p in glioma tumor cells
significantly promoted cell proliferation, suggesting a role of this miRNA in cell cycle regula‐
tion (101). A mechanistic study revealed that two target genes, retinoblastoma-like 1 (RBL1)
and RBL2, were involved in miR-106b-5p's regulation of cell proliferation (101). RBL proteins
were involved in genomic instability, coinciding with decreased DNA methylation and
increased acetylation of histone H3.
p27, one of the cyclin-dependent kinase inhibitor, inhibits cell cycle progression at the G1 phase
by blocking the activation of cyclin-CDK complexes (102). The downregulation of p27
expression by miRNAs could abrogate the cell cycle checkpoints and could increase DNA
damages in GBM cells. The regulatory effect of miR-221/222 on p27 and the subsequent effect
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on cell proliferation were also demonstrated in GBM cells (103). Moreover, p27 inhibition
abrogated the growth advantage of cells with miR221/miR-222 downregulation (103).
DNA mismatch repair (MMR) is a system for recognizing and correcting insertions, deletions,
and misincorporated bases at DNA replication and recombination. Deficiency of MMR system
can be a cause for the development and progression of GBMs. There are two essential members
of the DNA MMR genes, MutS homologs and MutL homologs. Computational algorithms
predicted, and subsequently in vitro studies confirmed, several essential MMR genes, includ‐
ing MLH1, MSH2, and MSH6, as potential binding sites for miR-155. miR-155 is known to
elevate its expression levels in primary and secondary GBMs (94).
As an important sensor in the DNA damage response, p53 functions to block the cell cycle to
repair damaged DNA. Several miRNAs affect p53 or p53-regulated genes via different
mechanisms. For instance, miR-125b, which has been shown to play a potential role in the
development of glioma stem cells (104), directly targets p53 by binding to 3′-UTR of p53 and
negatively regulates p53 expression (105). In addition, miR-125b negatively regulates MXD1
expression, an adaptor protein for MAD2L2 in the spindle assembly checkpoint. Moreover,
miR-29, commonly downregulated in GBMs, indirectly upregulates p53 by targeting PIK3R1
and CDC42 (106). Previous studies have shown that miR-34 is directly regulated by p53 and
represses various oncogenes, such as CCND1, CCNE2, CDK4, MET, MYC, SNAI1, and SIRT1.
However, these miR-34-targeting oncogenes are upregulated in GBM, because miR-34 is
usually downregulated (107). Several studies have shown that miR-34 is indispensable for the
DNA damage response, and miR-34a-regulated genes are strongly related with DNA repair
and apoptosis (108).
Ataxia telangiectasia mutated (ATM) is an important mediator in connecting DNA damage
signals to downstream events, including damage repair. miR-101, a miRNA downregulated
in GBM, could directly target ATM via the canonical action mechanism (109). In addition,
miR-101 also targets PRKDC (protein kinase, DNA activated, catalytic polypeptide) to regulate
nonhomologous end joining of DNA double-strand breaks (109).
3.7. Tumor-promoting inflammation and microRNAs
NF-kB is a transcription factor with pleiotropic activity owing to its central roles in inflamma‐
tory processes. A critical regulator of NF-kB activation is the IkB kinase (IKK-β) complex (110).
Ectopic expression of miR-218, which is downregulated in GBM, reduced NF-kB activity,
whereas inhibition of miR-218 enhanced the transcriptional activity of NF-kB (78). miR-218
could inactivate NF-kB signaling by directly targeting the 3′-UTR of the IKK-β (78). miR-21
was revealed as another regulator involved in the NF-kB-signaling pathway in GBM. Li et al.
confirmed LRRFIP1 (leucine-rich repeat interacting protein 1) as a direct target of miR-21 (111).
LRRFIP1 is a transcriptional repressor that preferentially binds to the GC-rich consensus
sequence and regulates expression of TNF, EGFR, and PDGFA signaling. miR-21 contributes
to drug resistance through the depression of LRRFIP1 expression, leading to the reduction of
cytotoxicity of chemotherapeutic drugs through the activation of the NF-kB pathway (111).
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miR-146a is known as miRNA associated with the innate immune response to microbial
infection (112). Promotor analysis revealed that miR-146a is a NF-kB-dependent miRNAs (112).
miR-146a has complementary sequences in the mRNA of the TNF receptor-associated factor
6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1), key adaptor molecules downstream
of toll-like and cytokine receptors (113). miR-146a overexpression enhanced apoptosis and
suppressed NF-kB activation in TMZ-treated GBM cells (114). Increased expression of
miR-146a was observed in glioneuronal lesions (115), and miR-146a expression in human glial
cells was strongly induced by IL-1β (115). miR-146a expression by transfection in astrocytes
regulated many mRNA expression levels, including those of IRAK-1, IRAK-2, and TRAF-6. In
addition, the expression of IL-6 and COX-2 was suppressed by miR-146a (115).
Recent evidence suggests that the signal transducer and activator of transcription (STAT)
family proteins play a crucial role in selectively inducing and maintaining a procarcinogenic
inflammatory microenvironment, both upon the initiation of malignant transformation and
during cancer progression (116). Upon upregulating miR-124, a miRNA downregulated in
GBM, specifically in glioma cancer stem cells (gCSC), the STAT3 pathway was inhibited, and
miR-124 reversed gCSC-mediated immunosuppression of T cell proliferation and induction
of regulatory T cells (Treg) (117). Systemic administration of miR-124-transfected T cell
transfers exerted potent antiglioma therapeutic effects in murine models of GBM (117).
Human glioma immune activation is potently elicited by a cytokine combination. Cytokines
such as IL-1β and TNFα induce the expression of miR-155 and miR-155*, the miRNAs crucial
in immunity and inflammation-induced oncogenesis, and this expression is dose dependently
suppressed by IRF3. Importantly, IRF3 also inhibits glioma proliferation, migration, and
invasion (118).
3.8. Reprogramming energy metabolism and microRNAs
Cellular metabolism of malignant tumor is considerably different from that of normal cell,
because of limitless proliferation and motility. (119). GBM cells uptake a large amount of
glucose, and aerobic glycolysis generates various substrates, such as fatty acids and nucleoti‐
des that are required for rapidly proliferating cells, and is associated with a survival advantage
in the tumor cells (Warburg effect). MR spectroscopy analyses have shown that as much as
90% of the glucose converts into lactate by aerobic glycolysis in GBM cells. Clinically, it is
known that the levels of lactate are elevated in GBM tissue compared with those in contralateral
normal brain tissue. In addition, lactate was shown to be high-grade gliomas than for low-
grade gliomas, and glutamate levels were significantly elevated for GBMs. Pretreatment F18-2-
fluoro-2-deoxy-D-glucose (FDG)-PET provides significant additional prognostic information
in high-grade gliomas (120).
In normal cells, the 5’-adenosine monophosphate-activated protein kinase (AMPK) pathway
is the major cellular sensor of energy availability (121), but its function in cancer is not clear.
AMPK is activated by metabolic stress to promote energy conservation and glucose uptake,
allowing cells to survive periods of low-energy availability. Allosteric interaction with elevated
intracellular AMP, which acts to inhibit dephosphorylation of AMPK (122), and phosphory‐
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lation at Thr172 by the protein kinase LKB1 are necessary for AMPK activation under condi‐
tions of bioenergetic stress (123).
Godlewski et al. identified miR-451 as a glioma-expressed miRNA that regulates the balance
of proliferation and migration in glioma cells in response to changes in glucose levels (124).
miR-451 regulates LKB1 activity through direct targeting of CAB39, a component of the active
LKB1 complex. Glucose deprivation was shown to reduce miR-451 levels (124). Thus, miR-451
plays an essential role in LKB1/AMPK signaling in glioma cells. When glucose is sufficient,
elevated miR-451 levels lead to reduced LKB1/AMPK pathway activation, which facilitates
cell proliferation by allowing unrestrained mTOR activity and reducing apoptosis. In contrast,
when glucose is limiting, miR-451 levels decline, allowing for increased CAB39 expression and
activation of AMPK by LKB1-mediated phosphorylation. This effect promotes cell survival in
response to metabolic stress and activates pathways involved in glioma motility.
Previous reports indicate that Myc is frequently upregulated or amplified in gliomas. As a
transcriptional factor, Myc interacts with many tumor-related oncogenes in glioma cells, such
as SPARC (125), GAS1 (126), and VEGF (127). c-Myc has been shown to stimulate glutamine
metabolism by increasing the expression of amino acid transporters and glutaminase (128).
Mechanistically, c-Myc expression has been shown to be suppressed by miR-145, which results
in reduced Lin28/Lin28b transcription (129). miR-145 is one of the miRNAs significantly
downregulated during malignant transformation in GBMs (130). miR-145 overexpression
suppresses the activity of oncogenic proteins Sox9, leading to reduction of cell proliferation
and invasion of GBM cells (130). Reduced levels of miR-145 may lead to metabolic remodeling
in glioma cells via Sox9, because Sox9 is known as a regulator of c-myc.
mTORC2 regulates c-Myc and glycolysis through FoxO acetylation, and mTORC2 controls
FoxO acetylation through class IIa HDACs, independently of Akt. FoxOs antagonize c-Myc
(131) by increasing the expression of miR-145 (132) and miR-34c (133), limiting c-Myc mRNA
stability and translation. In GBM cells, miR-34c levels were suppressed by FoxO1/FoxO3
knockdown, and miR-34c regulated c-Myc levels in GBM cells (134). The let-7 family has nine
members, and previous studies have identified the let-7 miRNA as a tumor suppressor that
regulates many important target genes during tumor development (135), such as RAS, Myc,
CCND1, LIN28, and HMGA2, which are involved in cell cycle progression and cell stemness.
The majority of let-7a miRNA functions in glioma malignancy are believed to involve K-Ras,
suggesting that let-7a-mediated manipulation of K-Ras may also be involved in regulating
glucose metabolism and GBM cell growth. The M2 isoform of pyruvate kinase (PK) is upre‐
gulated in most cancers, including GBM. The regulation of PKM2 was shown to occur via
miR-326 (136). There are four isoforms of PK in mammals, and PKM2 is highly expressed in
undifferentiated tissues and tumors. Because PKM2 is regulated by tyrosine phosphorylation
and is overexpressed in malignant tumors, PKM2 is considered as key molecule of aerobic
glycolysis. In addition, Zhou et al. reported that the human Nin one binding protein (NOB1),
which is required for the biogenesis and function of the 26S proteasome and plays a role in
RNA metabolism, is a direct target of miR-326 (137).
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3.9. Evading immune destruction and microRNAs
In the past, the infiltration of innate and adaptive immune cells into the tumor microenviron‐
ment was considered an immune attack against tumors. However, now, it is widely accepted
that immune cells also promote tumor initiation, progression, and metastasis (138). Tumor-
associated macrophages (TAMs) control the majority of immunological processes within
tumors exerting both regressive (M1) and progressive (M2) effects on tumor development
(139). However, the majority of TAMs exhibit an M2-like phenotype. Remarkably, miRs-29b,
miR-125a, miR-146a, and miR-155 are involved in the differentiation of TAMs (140). Overex‐
pression of miRNA-155 was shown to attenuate the production of cytokines (IL-6 and TNF-
α) by suppressing C/EBPβ expression, which led to an inversion of M2 into M1 macrophages
(141). M2 TAMs are capable of releasing anti-inflammatory cytokines such as the immuno‐
suppressive cytokine IL-10, which promotes tumor growth (142).
Natural killer T (NKT) cells are a subfraction of T cells. A large number of published studies
have demonstrated that NKT cells have miscellaneous functions in immune regulation, one
of which is that NKT cells are tumor cell killers, based on the production of antitumor
cytokines. In addition to contributing to immune protection, NKT cells are involved in immune
tolerance in the body. Tang et al. showed that glioma cells can induce immune-tolerant IL-6+
and IL-10+ NKT cells via miR-92a.
Another study revealed miR-221 and miR-222 as possible regulators of IFN pathways. Type-
I IFN receptor activation triggers the JAK-mediated tyrosine phosphorylation of STAT family
proteins. Zhang et al. found that STAT1 and STAT2 expression and phosphorylation were
upregulated after repression of miR-221/222 in U251 cells (143). Upregulation of STAT
pathway is controlled by the IFN-α activation after knockdown of miR-221/222 cluster in U251
glioma cells (143).
NKG2D is one of the major activating receptors of natural killer (NK) cells and binds to several
ligands (NKG2DL). NKG2D recognizes different MHC class I-homologous ligands
(NKG2DL), including the MHC class I-chain-related molecules A (MICA) and B (MICB) and
the UL16- binding proteins (ULBP)1-6 (144), which are also present on the surface of glioma
cells (145). Codo et al. reported that miR-20a, miR-93 or miR-106b regulates NKG2DL expres‐
sion in glioma cells (146), suggesting that the expression of miRNA-targeting NKG2DL may
contribute to the immune evasion of glioma cells at the level of the NKG2D recognition
pathway.
In addition, miRNA regulates immunocheckpoint molecules. miR-138 could bind the 3′-UTR
of CTLA-4 and PD-1, and transfection of human CD4+ T cells with miR-138 suppressed
expression of CTLA-4 and PD-1 (147). In vivo treatment in immunocompetent mice using
miR-138 revealed marked tumor regression and prolonged survival time. Moreover, inocu‐
lated tumors showed decrease in intratumoral regulatory T cell, CTLA-4, and PD-1 expression
(147). miR-138 exerts antiglioma efficacy by targeting immune checkpoints that may have
rapid translational potential as novel immunotherapeutic agents.
On the other hand, miRNA expression is transcriptionally regulated by various cytokines.
Ohno et al. analyzed the effect of IFN-β treatment on miR-21 expression in glioma cells and
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intracranial glioma xenografts (148). Systematic delivery of IFN-β markedly reduced the level
of miR-21 in glioma cells 6 hours after the addition of IFN-β.
4. Circulating microRNA in glioma patients
In 2008, Chim et al. firstly demonstrated the existence of placental miRNAs in maternal plasma
(149). In the same year, several miRNAs were detected in the serum of the tumor patients.
Quantitative real-time polymerase chain reaction (RT-PCR) analyses revealed sera levels of
miR-155, miR-210, and miR-21 are higher in diffuse large B-cell lymphoma patient sera than
healthy controls (150). To prevent degradation in the circulation, miRNAs are released by cells
in both exosomes and miRNA/protein complexes. Exosomes are lipid vesicles ranging between
50 and 100 nm in size and contain a range of molecules, including mRNA, miRNA, DNA, and
proteins. The detection of biomarkers within serum is attractive because of the relatively non-
invasive process of collection (Figure 1).
Figure 1. Cell-cell communication through circulating microRNAs. MicroRNAs contained in exosomes are released
from glioma cells where they can enter the blood-stream or CSF-stream and circulate through the body to distant sites.
These exosomal miRNAs are taken up by recipient cells, where the miRNAs can then suppress target genes in the re‐
cipient cells. Circulating miRNAs released by glioma cells may involve in growth signal, angiogenesis, anti-apoptosis,
tumor metabolism, and immunoregulation.
Over the past few years, researchers have investigated the capability of using miRNAs as blood
biomarkers for the diagnosis of tumors. Circulating miRNAs can be isolated from serum or
plasma, but recent studies have indicated plasma to be a more adequate source for miRNA
extraction (150). However, depending on plasma preparation, the level of circulating miRNA
can be altered. Cheng et al. showed that processing differences resulted in a variation in
residual platelet contamination in plasma and significant differences in miRNA abundance
(151). Consequently, supplementary centrifugation, the refusal of samples with platelet counts
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above a certain limit and the quantification of hemolysis are mandatory in accurately deter‐
mining miRNA levels in plasma.
Cerebrospinal fluid (CSF) is another useful biofluid and is in direct contact with the extracel‐
lular fluid of the brain. CSF has various functions, such as protecting the brain, transporting
biological substances, and excreting toxic and waste substances. Although the composition of
CSF reflects that of the blood plasma, active transport and secretions from the brain tissues
contribute to the composition of CSF. Therefore, the analyses of CSF can suggest biological
brain processes and is indispensable for understanding disorders of brain (152).
Clinically, histopathological examinations have been widely used to diagnose glioma, but they
are invasive because microsurgical resection or stereotactic biopsy is needed to acquire
specimens. In this context, it is of great interest to develop novel biomarkers for glioma.
Currently, several miRNAs have been identified as noninvasive biomarkers for the diagnosis
of cancers, including breast, lung, and gastric cancer. Previous studies have reported that
miRNAs can be detected in circulating exosomes in the serum or CSF of glioma, suggesting
that miRNAs might be useful biomarkers for glioma diagnosis. However, to effectively apply
these findings to clinical detection, further studies must be conducted (Table 2).
No. Authors Year  Source  Number
of
glioma
Number
of
control
microRNA
Blood
1 Skog 2008 serum 2
(GBM)
none let-7a, miR-15b, miR-16,
miR-19b, miR-21, miR-26a,
miR-27a, miR-92, miR-93,
miR-320, miR-20
2 Roth 2011 blood 20
(GBM)
20
(Healthy
controls)
miR-128(↑),
miR-342-3p(↓)
3 Wang 2012 plasma 50
(GBM)
10
(Healthy
controls)
miR-21(↑), miR-128(↓),
miR-342-3p(↓)
4 Yang 2013 serum 122
(Astro
cytoma)
123
(Healthy
controls)
miR-15b*(↓), miR-23a(↓), miR-133a(↓),
miR-150*(↓),miR-197(↓), miR-497(↓),
miR-548b-5p(↓)
5 Dong 2014 serum 3 (GBM) 3
(Healthy
controls)
miR-576-5p(↑), miR-340(↑),
miR-626(↑), miR-320(↓),
let-7g-5p(↓), miR-7-5p(↓)
6 Manterola 2014 serum 25 (GBM) 25
(Healthy
controls)
miR-320(↑), miR-574-3p(↑)
7 Shao 2015 plasma 70 (Glioma) 70
(Healthy
miR-454-3p(↑)
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No. Authors Year  Source  Number
of
glioma
Number
of
control
microRNA
controls)
8 Wu 2015 serum 83 (Glioma) 69
(Healthy
controls)
miR-29b(↓)
9 Liu 2015 serum 120 (Glioma) 120
(Healthy
controls)
miR-29b(↓)
10 Lai 2015 blood 136 (GBM) 50
(Healthy
controls)
miR-210(↑)
11 Sun 2015 serum 151 (Glioma) 53 (Healthy
controls),52
(Meningioma)
miR-128(↓)
12 Yue 2016 serum 20 (Glioma) 5
(Healthy
controls)
miR-205(↓)
13 Wei 2016 serum 33 (Glioma) 33
(Healthy
controls)
miR-125b(↓)
Cerebrospinal fluid (CSF)
1 Baraniskin 2012 CSF 10 (Glioma) 10 (Neurologic
disorders), 23
(CNS lymphoma),
7 (Metastatic
tumor)"
miR-15b(↑),
miR-21(↑)
2 Teplyuk 2012 CSF 19 (GBM) 15
(Non-neoplastic
control),44
(Metastatic
tumor), "
miR-10b(↑), miR-21(↑) ,
miR-200 family(↑)
3 Akers 2013 CSF 13 (GBM) 13
(Non-neoplastic
control)
miR-21(↑)
4 Shi 2015 CSF 8 (Astro
cytoma),
25 (Epen
dymoma),
45 (GBM)
none miR-21(↑)
Table 2. Circulating microrna in glioma patients.
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4.1. Serum and plasma
The first analysis of exosomes in serum identified the presence of 11 miRNAs in the samples
from two different patients with primary GBM in 2008 (153). However, the levels were
generally lower in exosomes but correlated well with the tumor profile (153). In 2011, Roth et
al. analyzed miRNA profiles from the blood of 20 patients with GBM and 20 matched healthy
controls (154). Among 1158 tested miRNAs, 52 were significantly deregulated, and of these,
two candidates, miR-128 (upregulated) and miR-342-3p (downregulated), remained the most
significant miRNAs. The altered expression of these two miRNAs was confirmed in a valida‐
tion cohort by RT-PCR. In this model, the discrimination between blood samples of patients
with GBM and healthy controls reached an accuracy of 81%, specificity of 79%, and sensitivity
of 83%. In 2012, Wang et al. determined the plasma miRNA levels of 50 patients with glioma
and 10 healthy donors using RT-PCR (155). The plasma level of miR-21 was increased and the
levels of miR-128 and miR-342-3p were significantly decreased in the patients with glioma
compared with those in normal controls. These miRNAs were able to discriminate patients
with glioma from healthy controls with high specificity and sensitivity. However, there were
not significant differences between patients with glioma and other brain tumors such as
meningioma or pituitary adenoma. Yang et al. performed genomewide serum miRNA analysis
using serum samples of 122 untreated astrocytoma patients and 123 normal controls (156). The
seven-miRNA panel (miR-15b*, miR-23a, miR-133a, miR-150*, miR-197, miR-497, and
miR-548b-5p) demonstrated a high sensitivity (88.00%) and specificity (97.87%) for malignant
astrocytoma prediction (156). These identified miRNAs also exhibited a global decrease in
tumor tissues relative to normal tissues. Interestingly, these miRNAs in serum were markedly
elevated after tumor removal.
In miRNA microarray analysis of the serum of patients with GBM and normal controls, 115
miRNAs were upregulated in the GBM group and 24 miRNAs were downregulated (157). In
these microRNAs, a six-membered serum miRNA expression profile (upregulated miRs;
miR-576-5p, miR-340, and miR-626, downregulated miRs; miR-320, let-7g-5p, and miR-7-5p)
could serve as a noninvasive biomarker for GBM diagnosis (157). Manterola et al. found that
the serum expression levels of miR-320 and miR-574-3p were significantly altered in the
patients with GBM (158). In addition, small noncoding RNA (RNU6-1) was an independent
predictor of a diagnosis of GBMs. Shao et al. compared the expression levels of miR-454-3p
between preoperative plasmas from 70 patients with glioma and 70 healthy controls and
between these preoperative and postoperative plasmas (159). The expression levels of
miR-454-3p in plasma in patients with glioma were significantly higher, and the area under
receiver operating characteristic (ROC) curve (AUC) of the expression of miR-454-3p for
glioma diagnosis was 0.9063. In addition, the expression levels of miR-454-3p in the postop‐
erative plasmas were significantly downregulated relative to the preoperative plasmas. Wu et
al. analyzed serum from 83 patients with glioma and 69 healthy controls and evaluated the
availability of the serum miR-29 family in the screening of glioma (160). The predictive value
of the serum miR-29 family for glioma was moderate (AUC = 0.74), but that in high-grade
glioma detection was sufficient (AUC = 0.81). Another study also showed that the expressions
of miR-29b in blood were significantly different compared with those of a healthy control (161).
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miR-125b is widely considered a tumor suppressor-miRNA and an ideal biomarker for clinical
diagnosis in various human cancers. The study of serum miR-125b from 33 gliomas and 33
healthy controls revealed that the serum miR-125b level was significantly lower in patients
with glioma (162). The ROC curve analysis yielded an AUC value of 0.839 (162). Furthermore,
a meta-analysis was conducted to assess the diagnostic accuracy of miR-125b in cancer
diagnosis, and the results revealed that employing miR-125b as a biomarker for cancer
detection achieved a sensitivity of 82% and a specificity of 77% (162).
miR-210 is reported to be another potentially useful biomarker in the serum of patients with
glioma. Lai et al. analyzed blood samples collected from patients with glioma (n=136) and
healthy controls (n=50) and revealed that an approximately sevenfold increase in miR-210
expression was detected in serum samples from patients with GBM relative to healthy controls
(163). miR-210 has been found to be upregulated in a variety of other solid tumor types and
potentially influences cellular function through diverse pathways; the miRNA has also been
correlated with hypoxia (164). A number of targets of miR-210 have been reported, including
VEGF (165), BCL2 (166), and E2F transcription factor 3 (167). Sun et al. analyzed the expression
levels of miR-128 in serum samples from 151 gliomas, 52 meningiomas, and 53 normal donors
and showed that miR-128 expression was significantly decreased in glioma preoperative
serum compared with others. ROC analyses showed that serum miR-128 levels were reliable
in distinguishing patients with glioma from normal controls and patients with meningioma,
with AUC values of 0.9095 and 0.8283, respectively (168). Although the mechanism has not
yet been clarified, the study demonstrated that serum miR-128 expression was significantly
elevated after surgery. miR-128 functions as a vital suppressor of tumorigenesis in glioma cells
and is reported to downregulate p70S6K1 and its downstream signaling molecules, including
VEGF and HIF-1. Another study showed that serum miR-205 expression was significantly
lower in patients with glioma than in healthy controls (p < 0.001) (169). Interestingly, serum
miR-205 expression levels were inversely correlated with pathological grades (169).
4.2. Cerebrospinal fluid
Baraniskin et al. (170) reported the first investigation of microRNA expression in CSF from
patients with glioma in 2012. The results demonstrated that miR-15b and miR-21 were
differentially expressed in CSF samples from patients with glioma compared with control
subjects with various neurologic disorders, including CNS lymphoma and carcinomatous
brain metastases. The combination of miR-15b and miR-21 resulted in increased diagnostic
accuracy, with 90% sensitivity and 100% specificity in distinguishing patients with glioma
from control subjects. Interestingly, miR-15 levels were significantly higher in glioma than in
CNS lymphoma or metastatic tumor; however, miR-21 levels were significantly lower in
glioma than in CNS lymphoma or metastatic tumor.
Teplyuk et al. (171) determined the CSF levels of several cancer-associated miRNAs for 118
patients diagnosed with different types of brain cancers. The levels of miR-10b and miR-21
were significantly increased in the CSF of patients with GBM and brain metastasis of breast
and lung cancer compared with non-neoplastic conditions. Members of the miR-200 family
were useful markers for discriminating between GBM and metastatic brain tumors. In
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addition, quantification of as few as seven microRNAs in CSF (miR-10b, miR-21, miR-125b,
miR-141, miR-200a, miR-200b, and miR-200c) enabled differential recognition of GBM and
metastatic brain tumor with high accuracy (91%–99%) (171).
Akers et al. analyzed extracellular vesicles (EVs) containing miRNAs in the CSF from patients
with GBMs. The EV fraction was isolated by differential centrifugation. Although the analytic
algorithm for quantitatively assessing EV miRNA remains underdeveloped, the authors
showed that the CSF miR-21 levels of patients with GBM were 10-fold higher than those in the
CSF of nononcologic patients (172).
Recently, another study reported results to those of Akers and coworkers. Exosomal miR-21
levels in the CSF of patients with glioma were found to be significantly higher than in controls,
although no difference was detected in serum-derived exosomal miR-21 expression. Interest‐
ingly, the CSF-derived exosomal miR-21 levels correlated with a level of dissemination and a
location of recurrence. Therefore, exosomal miR-21 in CSF may be a predictive marker for the
early stages of tumor recurrence or metastasis (173).
5. Future prospects
Over the past decade, our understanding of genetic alterations and the tumor-specific signal
pathways in glioma has been made, although this knowledge to date has not been translated
into the prognosis of the patients with glioma. However, a better understanding of key
pathways associated with gliomagenesis and malignant transformation could promise further
improvements in glioma therapy. Maximum safe resection followed by radiotherapy up to a
total dose of 60 Gy and TMZ-based chemotherapy have been established as a standard therapy,
but new molecular targeting drugs, including small-molecule cell cycle inhibitors and
biological and immune-based therapies have begun to yield promising results in clinical
studies.
Over the past two decades, miRNAs have emerged as molecules central to glioma biology.
miRNAs represent an additional layer of complexity in tumor biology and have been further
validated as regulators of processes fundamental to glioma. This field is rapidly changing.
Herein, we have reviewed the emerging roles of miRNAs as drivers of glioma formation and
progression with a focus on glioma hallmarks. miRNAs may be essential in glioma growth,
angiogenesis, invasion, genomic instability, tumor-promoting inflammation, and glioma-
specific metabolism. In recent years, functions of miRNAs in gliomagenesis and microenvir‐
onment have been considerably elucidated, and we have validated the tumor suppressive or
oncogenic functions of miRNAs in glioma. Now, we should move toward a next phase
involving clinical trials with miRNAs as glioma therapies. For example, miR-34, a tumor-
suppressive miRNA that simultaneously downregulates the expressions of MET, PDGFRA,
and CDK6 is currently in clinical trials as a directed therapy for advanced solid tumors. In
glioma, the restoration of miR-34a can possibly outperform any single targeted agents tailored
to those targets. There remain several problems to use miRNAs in glioma therapy. These
include not only accumulation of our knowledge of miRNAs’ biological functions in glioma,
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but also the development of new and safe methods for delivery to glioma cells. Although the
clinical application of miRNAs in GBM has yet to be realized, we believe the future of glioma
therapy could be bright.
In this review, we have also focused on circulating miRNAs of serum, plasma, and CSF in
patients with glioma. The use of miRNAs has several limitations, such as the diversity of
methodologies that exist for miRNA detection and the small cohort size for the validation steps
reported in current studies. Nonetheless, circulating miRNAs may exhibit diagnostic values,
the combination of biomarkers may improve the diagnostic accuracy, and the combination of
circulating miRNAs and other screening methods may be particularly useful in glioma
detection. However, a standard protocol of sample treatment and suitable internal controls
should be further established to make the level of detection comparable to that of other
methods before miRNA biomarkers are fully utilized in clinical practice.
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